<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">03445</article-id><article-id pub-id-type="doi">10.7554/eLife.03445</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-14328"><name><surname>Warkentin</surname><given-names>Alexander A</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18145"><name><surname>Lopez</surname><given-names>Michael S</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18146"><name><surname>Lasater</surname><given-names>Elisabeth A</given-names></name><aff><institution content-type="dept">Division of Hematology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18147"><name><surname>Lin</surname><given-names>Kimberly</given-names></name><aff><institution content-type="dept">Division of Hematology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-22983"><name><surname>He</surname><given-names>Bai-Liang</given-names></name><aff><institution content-type="dept">Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine</institution>, <institution>University of Hong Kong</institution>, <addr-line><named-content content-type="city">Pokfulam</named-content></addr-line>, <country>Hong Kong</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-22984"><name><surname>Leung</surname><given-names>Anskar Y H</given-names></name><aff><institution content-type="dept">Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine</institution>, <institution>University of Hong Kong</institution>, <addr-line><named-content content-type="city">Pokfulam</named-content></addr-line>, <country>Hong Kong</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18148"><name><surname>Smith</surname><given-names>Catherine C</given-names></name><aff><institution content-type="dept">Division of Hematology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18149"><name><surname>Shah</surname><given-names>Neil P</given-names></name><aff><institution content-type="dept">Division of Hematology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-13773"><name><surname>Shokat</surname><given-names>Kevan M</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country><email>Kevan.Shokat@ucsf.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1065"><name><surname>Cravatt</surname><given-names>Ben</given-names></name><role>Reviewing editor</role><aff><institution>The Scripps Research Institute</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>12</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e03445</elocation-id><history><date date-type="received"><day>24</day><month>05</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Â© 2014, Warkentin et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Warkentin et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Activating mutations in FLT3 confer poor prognosis for individuals with Acute Myeloid Leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions, but their utility has been hampered by acquired resistance and myelosuppression attributed to a 'synthetic lethal toxicity' arising from simultaneous inhibition of FLT3 and KIT. We report a novel chemical strategy for selective FLT3 inhibition while avoiding KIT inhibition with the staurosporine analog, Star 27. Star 27 maintains potency against FLT3 in proliferation assays of FLT3-transformed cells compared to KIT-transformed cells, shows no toxicity towards normal human hematopoiesis at concentrations that inhibit primary FLT3-mutant AML blast growth, and is active against mutations that confer resistance to clinical inhibitors. As a more complete understanding of kinase networks emerges it may be possible to define anti-targets such as KIT in the case of AML to allow improved kinase inhibitor design of clinical agents with enhanced efficacy and reduced toxicity.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>